The Drug That Dominated the Decade, Now Going Generic
Ozempic and its weight-loss sibling Wegovy have been the most-talked-about medications of the last few years, but for most Canadians, the price tag has kept them firmly out of reach. That could be about to change, at least partially, as Novo Nordisk's patent protections begin expiring in several countries, opening the door for cheaper generic versions.
Indian pharmaceutical manufacturers are among the first movers, with plans to produce biosimilar copies of semaglutide, the active ingredient in Ozempic and Wegovy, and sell them for roughly $14 USD per month. For context, Novo Nordisk's Wegovy pen currently starts at around 10,480 rupees in India and approximately $199 USD per month in the United States.
What This Means for the Global Weight-Loss Drug Market
India's pharmaceutical industry has a long history of producing high-quality, affordable generics that eventually reshape global drug access. Companies like Sun Pharma, Cipla, and Dr. Reddy's have done it before with HIV medications, insulin, and cancer drugs, and the same playbook is now being applied to GLP-1 receptor agonists.
The biosimilar versions won't be identical to the original, biologics are complex molecules that can't simply be copied the way a traditional pill can, but they are expected to be therapeutically comparable and will undergo regulatory scrutiny in their respective markets.
The Canadian Angle: Still Waiting, But Watching Closely
In Canada, Ozempic is approved for Type 2 diabetes management, while Wegovy received Health Canada approval for chronic weight management in 2022. Both remain expensive, and provincial drug plans offer inconsistent coverage, a patchwork that leaves many Canadians paying out of pocket.
The Indian generics aren't expected to land in Canadian pharmacies any time soon. Canada's regulatory pathway for biosimilars is strict, and Novo Nordisk still holds patent protections here that won't expire for several years. But the global pricing pressure that cheap generics create has historically pushed brand-name manufacturers to negotiate better deals with governments.
Health advocates in Canada have been calling for broader public coverage of GLP-1 drugs, arguing that the long-term healthcare savings from reducing obesity-related conditions, including diabetes, heart disease, and joint problems, far outweigh the upfront cost of medication.
A Preview of What's Possible
The Indian generic rollout is, in many ways, a preview of where the market is heading. As more patents expire globally and biosimilar manufacturing scales up, the price of semaglutide is widely expected to fall dramatically over the next decade.
For the millions of Canadians who have been told by their doctors that Ozempic or Wegovy could significantly improve their health but can't afford the monthly cost, that future can't come soon enough.
In the meantime, the news out of India is a useful reminder that the era of $1,000-a-month weight-loss drugs may not be permanent, and that affordability, not just efficacy, will define how transformative these medications truly become.
Source: National Post
